Actithera: Valuation, Funding & Investors
Actithera is a biotechnology company focused on developing innovative therapies using its proprietary three-pillar discovery platform, which is designed to enable prolonged radioligand tumor retention. The company is advancing clinical development of its fibroblast activation protein (FAP)-targeting candidate and aims to expand its therapeutic pipeline.
Leadership & Board
- Current Number of Employees
- 38
- Current LinkedIn Followers
- 3,961
Latest Estimated Valuation
- Total Amount Raised
- $76M
- Total Funding Rounds
- 1
- Latest Funding Amount
- $76M
- Latest Funding Round
- Series A
Company Momentum
PositiveActithera LinkedIn following is increasing, signaling rising market interest, while its workforce is growing, indicating business expansion.
Employee Trend
Actithera had 38 employees as of November 9, 2026. The number of employees increased by 0 (0.00%) week-over-week.
Social Trend
Actithera had 3,961 followers as of November 9, 2026. The number of followers increased by 24 (0.61%) week-over-week.
Funding Round
| Funding Date | Funding Round | Amount Raised | Post-Money Valuation |
|---|---|---|---|
| Jul 09, 2025 | Series A | $75.50M | ― |
Investors
| Investor Name | Funding Round |
|---|---|
| M Ventures | Series A |
| Sofinnova Partners | Series A |
| Surveyor Capital | Series A |
| Bioqube Ventures | Series A |
| Hadean Ventures | Series A |
| 4BIO Capital | Series A |
Similar Companies
A snapshot of private companies similar to Actithera, helping you discover and navigate related company profiles.
Related News and Analysis
